

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE INDICATED BELOW.

BY: Martha V. Helms

DATE: October 25, 2000



**PATENT**  
**BOX NON-FEE AMENDMENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Patent Application of : Group Art Unit: 1636  
Si-Yi Chen *et al.* :  
:   
:   
Appln. No.: 09/321,247 : Examiner: R. Schwartzman  
:   
Filed: May 27, 1999 :   
:   
For: INACTIVATION OF HIV CO-RECEPTORS : Attorney Docket  
AS THERAPY FOR HIV INFECTION : No. 443-2U2  
: (200443.0036)  
: (WFU-97-09)

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures," which Notice was provided by Office Communication dated **October 2, 2000** (Paper No. 6), enclosed herewith are the following:

- (X) Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 through 1.825;
- (X) Substitute Paper Copy (3 pages) of the Sequence Listing;
- (X) Substitute computer readable form (CRF) copy of the Sequence Listing;
- (X) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (Paper No. 6);
- (X) Other: Preliminary Amendment.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayments to Deposit Account 50-1017 (200443.0036). One additional copy of this paper is enclosed for accounting purposes.

Respectfully submitted,

**SI-YI CHEN *ET AL.***

OCTOBER 25, 2000  
(Date)

By:

Kathryn Doyle  
**KATHRYN DOYLE, Ph.D., J.D.**  
Registration No. 36,317  
**AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.**  
One Commerce Square  
2005 Market Street - Suite 2200  
Philadelphia, PA 19103  
Telephone: (215) 965-1200  
**Direct Dial: (215) 965-1284**  
Facsimile: (215) 965-1210  
E-Mail: [kdoyle@akingump.com](mailto:kdoyle@akingump.com)

KD/GHL  
Enclosures



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/321,247	05/27/99	CHEN	0443-202

000570 HM22/1002  
AKIN GUMP STRAUSS HAUER & FELD LLP  
ONE COMMERCE SQUARE  
2005 MARKET STREET SUITE 2200  
PHILADELPHIA PA 19103



EXAMINER SCHWARTZMAN, R
----------------------------

ART UNIT 1836	PAPER NUMBER 6
------------------	-------------------

DATE MAILED: 10/02/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



DEADLINE: 11/1/00



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
	6

Please find below a communication from the **EXAMINER** in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

This application contains sequences which are not identified by SEQ ID NO:#. All amino acid sequences which have four or more defined amino acid residues must be identified using the appropriate SEQ ID NO. If these sequences have not been included as part of the originally submitted SEQ ID listing, Applicant must provide an amended copy of both the paper and CRF listing including these sequences and a statement that the two are the same.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Karen A. Lacourciere whose telephone number is (703) 308-7523. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner George Elliott whose telephone number is (703) 308-4003. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

  
ROBERT A. SCHWARTZMAN  
PRIMARY EXAMINER

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Sequences not identified by SEQ ID NO:#

## Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**